Framework to identify innovative sources of value creation from platform technologies

Abstract

Platform technologies are fundamentally reshaping the pharmaceutical industry, offering unprecedented potential for innovation across multiple therapeutic areas. However, traditional valuation models, focused on single-asset metrics, struggle to capture the full spectrum of value these technologies create. This paper presents a comprehensive framework for evaluating the innovative sources of value creation enabled by platform technologies throughout the drug development lifecycle. Through a systematic literature review, in-depth case studies, and framework development, we provide a structured methodology for capturing the diverse benefits of these technologies. Our findings reveal that platform technologies generate value across strategic, technical, and adaptive dimensions, requiring a multifaceted valuation approach. The proposed Platform Value Identification across Strategic, Technical, and Adaptive domains Framework defines key value drivers, specifies quantitative assessment metrics, and provides implementation guidance to inform strategic decision-making in research and development investment, portfolio management, and business development. Application of the framework to case studies of Alnylam’s RNAi platform, Genentech’s therapeutic antibody platform, and Moderna’s mRNA platform demonstrates its broad utility and impact potential. By adopting this holistic, data-driven approach, stakeholders can better assess the long-term value and competitive advantages of well-implemented platform technologies, accelerating the development of transformative therapies for patients.